Editorial. Discusses the accuracy of the gold standard of endomyocardial biopsy (EMB) in rejection surveillance. Development of EMB to provide an objective measure of graft-host interaction; Nomenclature used to characterize rejection on EMB; Safety and utility of EMB in pediatrics; Immunosuppressive agents for the treatment of rejection.